Urovant Sciences to Present at the Jefferies 2019 Healthcare Conference
A live, audio webcast for this event will be available on the Investor Relations section of the Urovant website at http://ir.urovant.com for approximately three months.
Urovant Sciences is a clinical-stage biopharmaceutical company focused
on developing and commercializing innovative therapies for urologic
conditions. Urovant recently reported positive Phase 3 trial results for
its lead product candidate, vibegron, an oral, once-daily small molecule
beta-3 agonist being evaluated for overactive bladder (OAB). The
international, pivotal trial achieved co-primary endpoints and all seven
key secondary endpoints. In addition, vibegron is being evaluated in a
phase 3 study for the treatment of OAB in men with benign prostatic
hyperplasia and in a phase 2a study for abdominal pain associated with
irritable bowel syndrome. Urovant’s second product candidate, URO-902,
is a novel gene therapy being developed for patients with OAB who have
failed oral pharmacological therapy.